Catalyst Biosciences Announces Oral Presentation on Interim Phase 1/2 Data of Subcutaneous CB 2679d/ISU304 in Hemophilia B Patients at American Society for Hematology
CB 2679d demonstrated a 22-fold greater potency over BeneFIX and a longer mean residence time
Dr. Levy will present interim pharmacokinetic and pharmacodynamic results from intravenous and subcutaneous dosing of several subjects from
“All current FIX treatments require intravenous administration and do not provide sustained normal or even mild FIX trough levels,” said Dr. Levy. “However, due to its subcutaneous administration route and potential to normalize FIX levels, CB 2679d is an exciting potential new prophylactic treatment option for individuals, especially children, with hemophilia B. We look forward to announcing our top-line results by Q1 of 2018.”
Details for the oral presentation are as follows:
Presentation Title: | Phase 1/2 Trial of Subcutaneously Administered Factor IX Variant CB 2679d/ISU304: Pharmacokinetics and Activity |
Presenter: | Howard Levy, M.B.B.Ch., Ph.D., M.M.M. |
Session Title: | 322. Disorders of Coagulation or Fibrinolysis: Novel Therapies and Clinical Trials in Bleeding Disorders |
Date/Time: | Saturday, Dec. 9, 2017 at 10:15 a.m. EST |
Room: | Georgia World Congress Center, Bldg B, Lvl 2, B207-B208 |
About
Catalyst is a clinical-stage biopharmaceutical company developing novel medicines to address hematology indications. Catalyst is focused on the field of hemostasis, including the subcutaneous prophylaxis of hemophilia and facilitating surgery in individuals with hemophilia. For more information, please visit www.catbio.com.
Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding our strategy, the potential uses and benefits of CB 2679d and development plans for this product candidate are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Catalyst’s clinical trial timelines, including the anticipated completion of a Phase 1/2 proof-of-concept study for CB 2679d or the plans to have results from this study between the end of 2017 and the first quarter of 2018, the potential uses and benefits of subcutaneously dosed CB 2679d, and the Company’s belief regarding sufficiency of its existing capital resources to meet its projected operating requirements for at least the next 12 months. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Catalyst makes, including, but not limited to, the risk that clinical trials and studies may be delayed and may not have satisfactory outcomes, that potential adverse effects may arise from the testing or use of Catalyst’s products, the risk that costs required to develop or manufacture Catalyst’s products will be higher than anticipated, competition and other factors that affect our ability to successfully develop and commercialize our product candidates, and other risks described in the “Risk Factors” section of the Company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the
Contacts:
Investors:
1.650.871.0761
investors@catbio.com
Media
LifeSci Public Relations
1.646.751.4361
jo@lifescipublicrelations.com